Identification
NameNeflamapimod
Accession NumberDB07138  (DB12790)
TypeSmall Molecule
GroupsInvestigational
Description

Neflamapimod has been used in trials studying the treatment of Alzheimer's Disease and Mild Cognitive Impairment.

Structure
Thumb
SynonymsNot Available
External IDs VD-31,745 / VD-31745 / VRT-031745 / VX 745 / VX-745 / VX745
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIITYL52QM320
CAS number209410-46-8
WeightAverage: 436.262
Monoisotopic: 434.981144439
Chemical FormulaC19H9Cl2F2N3OS
InChI KeyVEPKQEUBKLEPRA-UHFFFAOYSA-N
InChI
InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H
IUPAC Name
5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one
SMILES
FC1=CC(F)=C(SC2=NN3C=NC(=O)C(=C3C=C2)C2=C(Cl)C=CC=C2Cl)C=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Mitogen-activated protein kinase 14ProteinunknownNot AvailableHumanQ16539 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentAlzheimer's Disease (AD)1
2Active Not RecruitingTreatmentAlzheimer's Disease (AD) / Mild Cognitive Impairment (MCI)1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000559 mg/mLALOGPS
logP5.17ALOGPS
logP4.89ChemAxon
logS-5.9ALOGPS
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area45.03 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity108.15 m3·mol-1ChemAxon
Polarizability38.75 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.944
Caco-2 permeable+0.5479
P-glycoprotein substrateNon-substrate0.8052
P-glycoprotein inhibitor INon-inhibitor0.5821
P-glycoprotein inhibitor IINon-inhibitor0.9321
Renal organic cation transporterNon-inhibitor0.7817
CYP450 2C9 substrateNon-substrate0.7705
CYP450 2D6 substrateNon-substrate0.808
CYP450 3A4 substrateSubstrate0.5676
CYP450 1A2 substrateInhibitor0.8606
CYP450 2C9 inhibitorInhibitor0.6849
CYP450 2D6 inhibitorNon-inhibitor0.8903
CYP450 2C19 inhibitorInhibitor0.6231
CYP450 3A4 inhibitorNon-inhibitor0.846
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7229
Ames testNon AMES toxic0.7209
CarcinogenicityNon-carcinogens0.8646
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2006 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9919
hERG inhibition (predictor II)Non-inhibitor0.8667
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as diarylthioethers. These are organosulfur compounds containing a thioether group that is substituted by two aryl groups.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganosulfur compounds
Sub ClassThioethers
Direct ParentDiarylthioethers
Alternative ParentsDichlorobenzenes / Thiophenol ethers / Fluorobenzenes / Pyrimidones / Aryl chlorides / Aryl fluorides / Pyridazines and derivatives / Heteroaromatic compounds / Vinylogous amides / Sulfenyl compounds
SubstituentsDiarylthioether / 1,3-dichlorobenzene / Thiophenol ether / Chlorobenzene / Fluorobenzene / Halobenzene / Pyrimidone / Aryl chloride / Aryl fluoride / Aryl halide
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein serine/threonine kinase activity
Specific Function:
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad r...
Gene Name:
MAPK14
Uniprot ID:
Q16539
Uniprot Name:
Mitogen-activated protein kinase 14
Molecular Weight:
41292.885 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  2. Duffy JP, Harrington EM, Salituro FG, Cochran JE, Green J, Gao H, Bemis GW, Evindar G, Galullo VP, Ford PJ, Germann UA, Wilson KP, Bellon SF, Chen G, Taslimi P, Jones P, Huang C, Pazhanisamy S, Wang YM, Murcko MA, Su MS: The Discovery of VX-745: A Novel and Selective p38alpha Kinase Inhibitor. ACS Med Chem Lett. 2011 Jul 28;2(10):758-63. doi: 10.1021/ml2001455. eCollection 2011 Oct 13. [PubMed:24900264 ]
Drug created on September 15, 2010 15:19 / Updated on June 30, 2017 00:50